Adjuvant chemotherapy and survival outcome in node-negative breast cancer with a 21-gene recurrence score of 26-30
Adjuvant chemotherapy and survival outcome in node-negative breast cancer with a 21-gene recurrence score of 26-30
复制标题
DOI：
10.2217/fon-2020-1315
复制
发表时间：
2021-02-19
期刊：
影响因子：
3.3
通讯作者：
Wu, San-Gang
中科院分区：
文献类型：
--
作者：
Yang, Shi-Ping;Yao, Jia;Wu, San-Gang
目的：探讨21基因复发评分为26 ~ 30分的早期乳腺癌患者化疗的获益情况。方法：我们在监测、流行病学和最终结果数据库中确定了3754例患者。结果：57.6%的患者接受了辅助化疗。肿瘤分级越高、肿瘤越大、年龄越小的患者接受化疗的可能性越大。与倾向评分匹配前（p = 0.016）和后（p = 0.043）未接受化疗的患者相比，接受化疗与更好的乳腺癌特异性生存率独立相关。敏感性分析显示，低分化或未分化疾病患者的生存期明显增加。结论：辅助化疗可改善21基因复发评分为26-30的早期乳腺癌的预后，特别是对高级别肿瘤患者。在目前的临床实践中，21基因复发评分已被开发用于基于预后风险分层的化疗决策，特别是对于肿瘤大小的患者
Aim: To investigate the benefit of chemotherapy among early-stage breast cancer patients with 21-gene recurrence scores of 26-30. Methods: We identified 3754 patients in the Surveillance, Epidemiology, and End Results database. Results: 57.6% of the patients received adjuvant chemotherapy. Patients with higher tumor grade, larger tumors and younger age were more likely to receive chemotherapy. The receipt of chemotherapy was independently associated with better breast cancer-specific survival than in patients without chemotherapy before (p = 0.016) and after (p = 0.043) propensity score matching. The sensitivity analyses showed that survival gain was pronounced in patients with poorly differentiated or undifferentiated disease. Conclusions: Adjuvant chemotherapy improves the outcome for early-stage breast cancer with 21-gene recurrence score of 26-30, especially for patients with high-grade tumors.Lay abstractIn current clinical practice, the 21-gene recurrence score has been developed for chemotherapy decision-making based on prognostic risk stratification, especially for patients with tumor size